# US 8,277,796 B2 · Regeneration and repair of neural tissue using postpartum-derived cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,277,796 B2
- Document ID: US8277796B2
- Status: Granted
- Kind: B2
- Application number: 12/429,849
- Filed: 2009-04-24
- Published: 2010-10-14
- Granted: 2012-10-02
- Earliest claimed: 2003-06-27
- Assignees: Advanced Technologies and Regenerative Medicine, LLC
- Inventors: Darin J. Messina; Sanjay Mistry; Alexander M. Harmon; Ian Ross Harris; Anthony J. Kihm; Agnieszka Seyda; Chin-Feng Yi; Anna Gosiewska
- Web page: https://patentgrep.com/patent/US8277796B2

## CPC

- A61K 35/51: Umbilical cord; Umbilical cord blood; Umbilical stem cells
- A61K 35/50: Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
- A61K 38/18: Growth factors; Growth regulators
- A61K 38/1808: {Epidermal growth factor [EGF] urogastrone}
- A61K 38/1825: {Fibroblast growth factor [FGF]}
- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 38/1841: {Transforming growth factor [TGF]}
- A61K 38/185: {Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3}
- A61K 38/1858: {Platelet-derived growth factor [PDGF]}
- A61K 38/1866: {Vascular endothelial growth factor [VEGF]}
- A61K 38/1891: {Angiogenesic factors; Angiogenin}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/204: {IL-6}
- A61K 38/2053: {IL-8}
- A61K 38/27: Growth hormone [GH], i.e. somatotropin
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 13/12: of the kidneys
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/04: for non-specific disorders of the connective tissue
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 39/06: Free radical scavengers or antioxidants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- C12N 5/0607: {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells C12N5/0696)}
- A61K 35/12: Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00)
- C12N 2500/32: Amino acids
- C12N 2500/34: Sugars
- C12N 2500/44: Thiols, e.g. mercaptoethanol
- C12N 2500/90: Serum-free medium, which may still contain naturally-sourced components
- C12N 2500/95: Protein-free medium and culture conditions
- C12N 2501/12: Hepatocyte growth factor [HGF]
- C12N 2501/21: Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
- C12N 2501/23: Interleukins [IL]
- C12N 2502/02: embryonic cells
- C12N 2506/02: from embryonic cells
- C12N 2506/03: from non-embryonic pluripotent stem cells
- C12N 2509/00: Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N 2533/50: Proteins
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Cells derived from postpartum umbilicus and placenta are disclosed. Pharmaceutical compositions, devices and methods for the regeneration or repair of neural tissue using the postpartum-derived cells are also disclosed.

## Claims

### Claim 1

A pharmaceutical composition for treating a patient having a neurodegenerative condition, comprising a pharmaceutically acceptable carrier and one or more cells in an amount effective to treat the neurodegenerative condition, wherein said cells are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype; wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and wherein said cells lack production of CD117.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1 wherein said cells produce each of CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, PD-L2 and HLA-A,B,C.

### Claim 3 (depends on 2)

The pharmaceutical composition of claim 2 wherein said cells lack the production of each of CD31, CD34, CD45, CD80, CD86, CD141, CD178, B7-H2, HLA-G, and HLA-DR,DP,DQ.

### Claim 4

A pharmaceutical composition for treating a patient having a neurodegenerative condition, comprising a pharmaceutically acceptable carrier and cells induced in vitro to differentiate into a neural lineage prior to formulation of the composition, wherein the cells prior to differentiation are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing cells isolated from human umbilical cord tissue substantially free of blood, and wherein the cells prior to differentiation have the following characteristics:
a) capable of self-renewal and expansion in culture;
b) the potential to differentiate into cells of at least a neural phenotype;
c) exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and
d) lack production of CD117.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the cells are genetically engineered to produce a gene product that promotes treatment of the neurodegenerative condition.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, comprising at least one other agent selected from the group consisting of an anti-inflammatory agent, and anti-apoptotic agent, an antioxidant and a growth factor.

### Claim 7

A kit for treating a patient having optic nerve damage, the kit comprising a pharmaceutically acceptable carrier, a population of cells and instructions for using the kit in a method of treating the patient, wherein said cells are isolated from human umbilical cord tissue substantially free of blood, or are generated by culturing said isolated cells, wherein said cells are capable of self-renewal and expansion in culture and have the potential to differentiate into cells of at least a neural phenotype; wherein said cells exhibit the ability to undergo at least about 40 doublings in culture without a change in karyotype; and wherein said cells lack production of CD117.
